In vivoT-cell depletion using alemtuzumab in family and unrelated donor transplantation for pediatric non-malignant disease achieves engraftment with low incidence of graft vs. host disease

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

(2014) M Bhatia et al.   BONE MARROW TRANSPLANTATION

Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation

(2013) J C Marsh et al.   BONE MARROW TRANSPLANTATION

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution

(2012) Jason Law et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children’s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry

(2012) Richard Mitchell et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia

(2012) P. Veys et al.   BLOOD

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience

(2012) Marion Strullu et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Acute graft-versus-host disease in pediatric allogeneic hematopoietic stem cell transplantation. Single-center experience during 10 yr

(2012) Maura Faraci et al.   PEDIATRIC TRANSPLANTATION

Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now

(2011) M. M. Hsieh et al.   BLOOD

Chronic norovirus infection in pediatric hematopoietic stem cell transplant recipients: A cause of prolonged intestinal failure requiring intensive nutritional support

(2011) M. A. Saif et al.   PEDIATRIC TRANSPLANTATION

Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT

(2010) D M Mickelson et al.   BONE MARROW TRANSPLANTATION

Chronic Graft-Versus-Host Disease (GVHD) in Children

(2010) Kristin Baird et al.   PEDIATRIC CLINICS OF NORTH AMERICA

Prognostic Utility of Routine Chimerism Testing at 2 to 6 Months after Allogeneic Hematopoietic Cell Transplantation

(2009) Ghada I. Mossallam et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy

(2009) Robert F. Wynn et al.   JOURNAL OF PEDIATRICS

Graft-versus-host disease after donor leukocyte infusions: presentation and management

(2008) Noelle V. Frey et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Lack of utility of chimerism studies obtained 2–3 months after myeloablative hematopoietic cell transplantation for ALL

(2008) K C Doney et al.   BONE MARROW TRANSPLANTATION

Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab

(2008) S W Bokhari et al.   BONE MARROW TRANSPLANTATION

Allogeneic stem cell transplantation for thalassemia major

(2008) E. Angelucci et al.   HAEMATOLOGICA

Use of Enzyme Replacement Therapy (Laronidase) before Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis I: Experience in 18 Patients

(2008) Robert F. Wynn et al.   JOURNAL OF PEDIATRICS